Medical Information

Although clofazimine is an important drug for the treatment of leprosy and mycobacterial infections, it is not suitable for everyone.The following is a detailed introduction.

I.Patients with severe hepatic impairment

1.Contraindication and caution principles

Clofazimine is mainly metabolized by the liver and excreted via bile.Patients with severe hepatic impairment (such as decompensated cirrhosis, severe hepatitis, or Child-Pugh class C liver function) should not use it or should strictly avoid it.

Patients with moderate hepatic impairment should use it with caution, only after a physician has assessed that the benefits outweigh the risks, and with close monitoring.

2.Risk mechanisms

Drug accumulation in the liver can increase the burden on hepatocytes and may induce or worsen jaundice, elevated transaminases, and even liver failure.

In addition, clofazimine can cause abnormal bilirubin metabolism, interfering with the assessment of pre-existing liver disease.

3.Monitoring requirements

Those who must use it should undergo regular liver function tests (transaminases, bilirubin, albumin, coagulation function).If fatigue, loss of appetite, dark urine, or yellowing of the skin and sclera occurs, the drug should be stopped immediately and medical attention sought.

Avoid concomitant use with other hepatotoxic drugs and abstain from alcohol.

II.Pregnant patients

1.Medication principles

Clofazimine is generally not recommended during pregnancy unless the maternal condition (such as active leprosy) truly requires treatment and there is no alternative, in which case a specialist must decide after weighing the benefits and risks.

Those planning pregnancy should communicate with their physician in advance to adjust the regimen.

2.Potential risks

Clofazimine can cross the placenta.Animal studies and limited human data suggest concerns about embryotoxicity; drug accumulation in fetal tissues may cause skin pigmentation in the newborn.

In addition, pregnancy is often accompanied by fluctuations in liver function, further increasing the risk of medication use.

3.Lactation and neonates

The drug can be secreted into breast milk, and use in breastfeeding women requires assessment; if exposed during pregnancy or lactation, the newborn should be observed for skin color and liver function after birth, with pediatric follow-up if necessary.

III.General precautions

1.Before medication, patients must inform the physician in detail of any history of liver disease, pregnancy, and breastfeeding status.

2.Severe hepatic impairment is an explicit contraindication, and the drug must not be used on one's own.

3.Medication during pregnancy requires individualized decision-making, and the drug must not be taken or stopped without authorization.

4.Attend regular follow-up visits during treatment and seek medical attention promptly if abnormal symptoms occur.